CFDE Data Portal | Search OSGEPL1-AS1

	Label	Description
	OSGEPL1-AS1 associations Collection (Entity type)	Associations for OSGEPL1-AS1_associations
	OSGEPL1-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	OSGEPL1-AS1 Gene (Entity type)	ENSG00000253559 - OSGEPL1 antisense RNA 1
	GSE135514 8 V 7 DASATINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE210476 11 V 4 RUTAECARPINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 5 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193258,GSE193259 5 V 4 OSIMERTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE171837 0 V 3 BORTEZOMIB MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

OSGEPL1-AS1 associations

Associations for OSGEPL1-AS1_associations

OSGEPL1-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

OSGEPL1-AS1

ENSG00000253559 - OSGEPL1 antisense RNA 1

GSE135514 8 V 7 DASATINIB HUMAN DN

A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN UP

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

A Gene Set from LINCS

GSE210476 11 V 4 RUTAECARPINE HUMAN DN

A Gene Set from LINCS

GSE146358 dopamine 5 v 2 human up

A Gene Set from LINCS

GSE193258,GSE193259 5 V 4 OSIMERTINIB HUMAN UP

A Gene Set from LINCS

GSE171837 0 V 3 BORTEZOMIB MOUSE UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.